Selecting the dosage of ceftazidime–avibactam in the perfect storm of nosocomial pneumonia

Personalized antibiotic dosing for the critically ill

(2019) Jason A. Roberts et al.   INTENSIVE CARE MEDICINE

Geographical and temporal variation in the frequency and antimicrobial susceptibility of bacteria isolated from patients hospitalized with bacterial pneumonia: results from 20 years of the SENTRY Antimicrobial Surveillance Program (1997–2016)

(2019) Helio S Sader et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Dose Selection and Validation for Ceftazidime-Avibactam in Adults with Complicated Intra-abdominal Infections, Complicated Urinary Tract Infections, and Nosocomial Pneumonia

(2019) Shampa Das et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Randomized Trial of Ceftazidime-Avibactam vs Meropenem for Treatment of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (REPROVE): Analyses per US FDA–Specified End Points

(2019) Antoni Torres et al.   Open Forum Infectious Diseases

Avibactam Pharmacokinetic/Pharmacodynamic Targets

(2018) Wright W. Nichols et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial

(2018) Antoni Torres et al.   LANCET INFECTIOUS DISEASES

Clinical applications of population pharmacokinetic models of antibiotics: Challenges and perspectives

(2018) Femke de Velde et al.   PHARMACOLOGICAL RESEARCH

Ceftazidime-Avibactam Susceptibility Breakpoints Against Enterobacteriaceae and Pseudomonas aeruginosa

(2018) Wright W. Nichols et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Ceftazidime-Avibactam Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Across Adult Indications and Patient Subgroups

(2018) Jianguo Li et al.   CTS-Clinical and Translational Science

Population Pharmacokinetic Modelling of Ceftazidime and Avibactam in the Plasma and Epithelial Lining Fluid of Healthy Volunteers

(2018) Richard Dimelow et al.   Drugs in research & development

Changes in Prevalence of Health Care–Associated Infections in U.S. Hospitals

(2018) Shelley S. Magill et al.   NEW ENGLAND JOURNAL OF MEDICINE

The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections

(2017) T. Tängdén et al.   INTENSIVE CARE MEDICINE

A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia

(2017) Xinyu Qin et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

In VitroActivity of Ceftazidime-Avibactam against Contemporary Pseudomonas aeruginosa Isolates from U.S. Medical Centers by Census Region, 2014

(2016) Michael D. Huband et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroSusceptibility of Global Surveillance Isolates of Pseudomonas aeruginosa to Ceftazidime-Avibactam (INFORM 2012 to 2014)

(2016) Wright W. Nichols et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroSusceptibility to Ceftazidime-Avibactam of Carbapenem-Nonsusceptible Enterobacteriaceae Isolates Collected during the INFORM Global Surveillance Study (2012 to 2014)

(2016) Boudewijn L. M. de Jonge et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program

(2016) Florian M. Wagenlehner et al.   CLINICAL INFECTIOUS DISEASES

Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program

(2016) John E. Mazuski et al.   CLINICAL INFECTIOUS DISEASES

Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society

(2016) Andre C. Kalil et al.   CLINICAL INFECTIOUS DISEASES

Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing

(2016) Nikolas J. Onufrak et al.   CLINICAL THERAPEUTICS

In vitro activity of ceftazidime/avibactam against Gram-negative pathogens isolated from pneumonia in hospitalised patients, including ventilated patients

(2016) Robert K. Flamm et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Phase 1 Study Assessing the Pharmacokinetic Profile and Safety of Avibactam in Patients With Renal Impairment

(2016) Henri Merdjan et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study

(2016) Yehuda Carmeli et al.   LANCET INFECTIOUS DISEASES

Pharmacokinetics and Penetration of Ceftazidime and Avibactam into Epithelial Lining Fluid in Thigh- and Lung-Infected Mice

(2015) Johanna Berkhout et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacodynamics of Ceftazidime and Avibactam in Neutropenic Mice with Thigh or Lung Infection

(2015) Johanna Berkhout et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Ceftazidime-Avibactam Activity against Multidrug-Resistant Pseudomonas aeruginosa Isolated in U.S. Medical Centers in 2012 and 2013

(2015) Helio S. Sader et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens

(2015) David P. Nicolau et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Applications of the pharmacokinetic/pharmacodynamic (PK/PD) analysis of antimicrobial agents

(2015) Eduardo Asín-Prieto et al.   JOURNAL OF INFECTION AND CHEMOTHERAPY

Activities of Ceftazidime and Avibactam against β-Lactamase-Producing Enterobacteriaceae in a Hollow-Fiber Pharmacodynamic Model

(2014) Ken Coleman et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Microbiological interaction studies between ceftazidime-avibactam and pulmonary surfactant and between ceftazidime-avibactam and antibacterial agents of other classes

(2014) John Dallow et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: Results from the SENTRY Antimicrobial Surveillance Program, 2009–2012

(2014) Helio S. Sader et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions

(2014) Jason A Roberts et al.   LANCET INFECTIOUS DISEASES

In VitroActivities of Ceftazidime-Avibactam and Aztreonam-Avibactam against 372 Gram-Negative Bacilli Collected in 2011 and 2012 from 11 Teaching Hospitals in China

(2013) Xiaojuan Wang et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinical Pharmacodynamics of Antipseudomonal Cephalosporins in Patients with Ventilator-Associated Pneumonia

(2013) Shawn H. MacVane et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Background and Rationale for Revised Clinical and Laboratory Standards Institute Interpretive Criteria (Breakpoints) for Enterobacteriaceae andPseudomonas aeruginosa:I. Cephalosporins and Aztreonam

(2013) Michael N. Dudley et al.   CLINICAL INFECTIOUS DISEASES

Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial

(2013) Christopher Lucasti et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Avibactam reverts the ceftazidime MIC90 of European Gram-negative bacterial clinical isolates to the epidemiological cut-off value

(2013) Robert K. Flamm et al.   JOURNAL OF CHEMOTHERAPY

Augmented renal clearance is a common finding with worse clinical outcome in critically ill patients receiving antimicrobial therapy

(2013) Barbara O.M. Claus et al.   JOURNAL OF CRITICAL CARE

In VitroAntibacterial Activity of the Ceftazidime-Avibactam (NXL104) Combination against Pseudomonas aeruginosa Clinical Isolates

(2012) Premavathy Levasseur et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacy and safety of ceftazidime–avibactam versus imipenem–cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study

(2012) José A. Vazquez et al.   CURRENT MEDICAL RESEARCH AND OPINION

Management of ventilator-associated pneumonia: epidemiology, diagnosis and antimicrobial therapy

(2012) Matteo Bassetti et al.   Expert Review of Anti-Infective Therapy

What's behind the failure of emerging antibiotics in the critically ill? Understanding the impact of altered pharmacokinetics and augmented renal clearance

(2012) Andrew A. Udy et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia

(2012) A. E. Muller et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In Vitro Activity of Ceftazidime Combined with NXL104 versus Pseudomonas aeruginosa Isolates Obtained from Patients in Canadian Hospitals (CANWARD 2009 Study)

(2011) A. Walkty et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach

(2011) J.W. Mouton et al.   CLINICAL MICROBIOLOGY AND INFECTION

Pharmacokinetic‐Pharmacodynamic Considerations in the Design of Hospital‐Acquired or Ventilator‐Associated Bacterial Pneumonia Studies: Look before You Leap!

(2010) Paul G. Ambrose et al.   CLINICAL INFECTIOUS DISEASES

Integrated Analysis of CANVAS 1 and 2: Phase 3, Multicenter, Randomized, Double‐Blind Studies to Evaluate the Safety and Efficacy of Ceftaroline versus Vancomycin plus Aztreonam in Complicated Skin and Skin‐Structure Infection

(2010) G. Ralph Corey et al.   CLINICAL INFECTIOUS DISEASES

Microbial Etiologies of Hospital‐Acquired Bacterial Pneumonia and Ventilator‐Associated Bacterial Pneumonia

(2010) Ronald N. Jones   CLINICAL INFECTIOUS DISEASES

Identifying Exposure Targets for Treatment of Staphylococcal Pneumonia with Ceftobiprole

(2009) K. A. Rodvold et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY